Microbiota dynamics in patients treated with fecal microbiota transplantation for recurrent Clostridium difficile infection
Clostridium difficile causes antibiotic-associated diarrhea and pseudomembraneous colitis and is responsible for a large and increasing fraction of hospital-acquired infections. Fecal microbiota transplantation (FMT) is an alternate treatment option for recurrent C. difficile infection (RCDI) refrac...
Gespeichert in:
Veröffentlicht in: | PloS one 2013-11, Vol.8 (11), p.e81330-e81330 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | e81330 |
---|---|
container_issue | 11 |
container_start_page | e81330 |
container_title | PloS one |
container_volume | 8 |
creator | Song, Yang Garg, Shashank Girotra, Mohit Maddox, Cynthia von Rosenvinge, Erik C Dutta, Anand Dutta, Sudhir Fricke, W Florian |
description | Clostridium difficile causes antibiotic-associated diarrhea and pseudomembraneous colitis and is responsible for a large and increasing fraction of hospital-acquired infections. Fecal microbiota transplantation (FMT) is an alternate treatment option for recurrent C. difficile infection (RCDI) refractory to antibiotic therapy. It has recently been discussed favorably in the clinical and scientific communities and is receiving increasing public attention. However, short- and long-term health consequences of FMT remain a concern, as the effects of the transplanted microbiota on the patient remain unknown. To shed light on microbial events associated with RCDI and treatment by FMT, we performed fecal microbiota analysis by 16S rRNA gene amplicon pyrosequencing of 14 pairs of healthy donors and RCDI patients treated successfully by FMT. Post-FMT patient and healthy donor samples collected up to one year after FMT were studied longitudinally, including one post-FMT patient with antibiotic-associated relapse three months after FMT. This analysis allowed us not only to confirm prior reports that RCDI is associated with reduced diversity and compositional changes in the fecal microbiota, but also to characterize previously undocumented post-FMT microbiota dynamics. Members of the Streptococcaceae, Enterococcaceae, or Enterobacteriaceae were significantly increased and putative butyrate producers, such as Lachnospiraceae and Ruminococcaceae were significantly reduced in samples from RCDI patients before FMT as compared to post-FMT patient and healthy donor samples. RCDI patient samples showed more case-specific variations than post-FMT patient and healthy donor samples. However, none of the bacterial groups were invariably associated with RCDI or successful treatment by FMT. Overall microbiota compositions in post-FMT patients, specifically abundances of the above-mentioned Firmicutes, continued to change for at least 16 weeks after FMT, suggesting that full microbiota recovery from RCDI may take much longer than expected based on the disappearance of diarrheal symptoms immediately after FMT. |
doi_str_mv | 10.1371/journal.pone.0081330 |
format | Article |
fullrecord | <record><control><sourceid>proquest_plos_</sourceid><recordid>TN_cdi_plos_journals_1461963126</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_0baf93419ab64cff96d92a8e6e88dcd8</doaj_id><sourcerecordid>3138466251</sourcerecordid><originalsourceid>FETCH-LOGICAL-c526t-92d1cd2e65cd032cc26f759a9dba04d7adeee783b045013c8f82008c959718e63</originalsourceid><addsrcrecordid>eNptUs1u1DAYjBCIlsIbILDEhcsu_kkc-4KEVgUqFXGBs-XYn1uvkjjYTlHFy9fppqVFnGzZM_ONx1NVrwneEtaSD_swx1H32ymMsMVYEMbwk-qYSEY3nGL29MH-qHqR0h7jhgnOn1dHtGaY4ZodV3--eRND50PWyF6PevAmIT-iSWcPY04oR9AZLPrt8yVyYHSPhr-UHPWYpl6PueDDiFyIKIKZYyxktOtDytFbPw_Ieue88T0U9SKzoF9Wz5zuE7xa15Pq5-fTH7uvm_PvX852n843pqE8byS1xFgKvDEWM2oM5a5tpJa207i2rbYA0ArW4brBhBnhBC15GNnIlgjg7KR6e9Cdih-15pYUqTmRnBG6IM4OCBv0Xk3RDzpeq6C9uj0I8ULpmL3pQeFOO8lqInXHa-Oc5FZSXcaAENZYUbQ-rtPmbgBrShBR949EH9-M_lJdhCvFRL14KQLvV4EYfs2Qshp8MtCXlCHMt74bIlgxUaDv_oH-_3X1AVW-LaUI7t4MwWrp0h1LLV1Sa5cK7c3Dh9yT7srDbgByGsuI</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1461963126</pqid></control><display><type>article</type><title>Microbiota dynamics in patients treated with fecal microbiota transplantation for recurrent Clostridium difficile infection</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Public Library of Science (PLoS) Journals Open Access</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Free Full-Text Journals in Chemistry</source><creator>Song, Yang ; Garg, Shashank ; Girotra, Mohit ; Maddox, Cynthia ; von Rosenvinge, Erik C ; Dutta, Anand ; Dutta, Sudhir ; Fricke, W Florian</creator><contributor>Berg, Gabriele</contributor><creatorcontrib>Song, Yang ; Garg, Shashank ; Girotra, Mohit ; Maddox, Cynthia ; von Rosenvinge, Erik C ; Dutta, Anand ; Dutta, Sudhir ; Fricke, W Florian ; Berg, Gabriele</creatorcontrib><description>Clostridium difficile causes antibiotic-associated diarrhea and pseudomembraneous colitis and is responsible for a large and increasing fraction of hospital-acquired infections. Fecal microbiota transplantation (FMT) is an alternate treatment option for recurrent C. difficile infection (RCDI) refractory to antibiotic therapy. It has recently been discussed favorably in the clinical and scientific communities and is receiving increasing public attention. However, short- and long-term health consequences of FMT remain a concern, as the effects of the transplanted microbiota on the patient remain unknown. To shed light on microbial events associated with RCDI and treatment by FMT, we performed fecal microbiota analysis by 16S rRNA gene amplicon pyrosequencing of 14 pairs of healthy donors and RCDI patients treated successfully by FMT. Post-FMT patient and healthy donor samples collected up to one year after FMT were studied longitudinally, including one post-FMT patient with antibiotic-associated relapse three months after FMT. This analysis allowed us not only to confirm prior reports that RCDI is associated with reduced diversity and compositional changes in the fecal microbiota, but also to characterize previously undocumented post-FMT microbiota dynamics. Members of the Streptococcaceae, Enterococcaceae, or Enterobacteriaceae were significantly increased and putative butyrate producers, such as Lachnospiraceae and Ruminococcaceae were significantly reduced in samples from RCDI patients before FMT as compared to post-FMT patient and healthy donor samples. RCDI patient samples showed more case-specific variations than post-FMT patient and healthy donor samples. However, none of the bacterial groups were invariably associated with RCDI or successful treatment by FMT. Overall microbiota compositions in post-FMT patients, specifically abundances of the above-mentioned Firmicutes, continued to change for at least 16 weeks after FMT, suggesting that full microbiota recovery from RCDI may take much longer than expected based on the disappearance of diarrheal symptoms immediately after FMT.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0081330</identifier><identifier>PMID: 24303043</identifier><language>eng</language><publisher>United States: Public Library of Science</publisher><subject>Aged ; Anti-Bacterial Agents - pharmacology ; Antibiotics ; Bacteria ; Biodiversity ; Biological Therapy - methods ; Clostridium difficile ; Colitis ; Diarrhea ; Disease ; Enterocolitis, Pseudomembranous - microbiology ; Enterocolitis, Pseudomembranous - therapy ; Fecal microflora ; Feces ; Feces - microbiology ; Female ; Firmicutes ; Follow-Up Studies ; Gastroenterology ; Genomes ; Hospitals ; Humans ; Male ; Medicine ; Metagenome ; Microbiota ; Microorganisms ; Middle Aged ; Patients ; Recurrent infection ; RNA, Ribosomal, 16S ; rRNA 16S ; Staphylococcus infections ; Transplantation ; Transplants & implants ; Treatment Outcome</subject><ispartof>PloS one, 2013-11, Vol.8 (11), p.e81330-e81330</ispartof><rights>2013 Song et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/3.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2013 Song et al 2013 Song et al</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c526t-92d1cd2e65cd032cc26f759a9dba04d7adeee783b045013c8f82008c959718e63</citedby><cites>FETCH-LOGICAL-c526t-92d1cd2e65cd032cc26f759a9dba04d7adeee783b045013c8f82008c959718e63</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3841263/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3841263/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,315,729,782,786,866,887,2104,2930,23873,27931,27932,53798,53800</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24303043$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Berg, Gabriele</contributor><creatorcontrib>Song, Yang</creatorcontrib><creatorcontrib>Garg, Shashank</creatorcontrib><creatorcontrib>Girotra, Mohit</creatorcontrib><creatorcontrib>Maddox, Cynthia</creatorcontrib><creatorcontrib>von Rosenvinge, Erik C</creatorcontrib><creatorcontrib>Dutta, Anand</creatorcontrib><creatorcontrib>Dutta, Sudhir</creatorcontrib><creatorcontrib>Fricke, W Florian</creatorcontrib><title>Microbiota dynamics in patients treated with fecal microbiota transplantation for recurrent Clostridium difficile infection</title><title>PloS one</title><addtitle>PLoS One</addtitle><description>Clostridium difficile causes antibiotic-associated diarrhea and pseudomembraneous colitis and is responsible for a large and increasing fraction of hospital-acquired infections. Fecal microbiota transplantation (FMT) is an alternate treatment option for recurrent C. difficile infection (RCDI) refractory to antibiotic therapy. It has recently been discussed favorably in the clinical and scientific communities and is receiving increasing public attention. However, short- and long-term health consequences of FMT remain a concern, as the effects of the transplanted microbiota on the patient remain unknown. To shed light on microbial events associated with RCDI and treatment by FMT, we performed fecal microbiota analysis by 16S rRNA gene amplicon pyrosequencing of 14 pairs of healthy donors and RCDI patients treated successfully by FMT. Post-FMT patient and healthy donor samples collected up to one year after FMT were studied longitudinally, including one post-FMT patient with antibiotic-associated relapse three months after FMT. This analysis allowed us not only to confirm prior reports that RCDI is associated with reduced diversity and compositional changes in the fecal microbiota, but also to characterize previously undocumented post-FMT microbiota dynamics. Members of the Streptococcaceae, Enterococcaceae, or Enterobacteriaceae were significantly increased and putative butyrate producers, such as Lachnospiraceae and Ruminococcaceae were significantly reduced in samples from RCDI patients before FMT as compared to post-FMT patient and healthy donor samples. RCDI patient samples showed more case-specific variations than post-FMT patient and healthy donor samples. However, none of the bacterial groups were invariably associated with RCDI or successful treatment by FMT. Overall microbiota compositions in post-FMT patients, specifically abundances of the above-mentioned Firmicutes, continued to change for at least 16 weeks after FMT, suggesting that full microbiota recovery from RCDI may take much longer than expected based on the disappearance of diarrheal symptoms immediately after FMT.</description><subject>Aged</subject><subject>Anti-Bacterial Agents - pharmacology</subject><subject>Antibiotics</subject><subject>Bacteria</subject><subject>Biodiversity</subject><subject>Biological Therapy - methods</subject><subject>Clostridium difficile</subject><subject>Colitis</subject><subject>Diarrhea</subject><subject>Disease</subject><subject>Enterocolitis, Pseudomembranous - microbiology</subject><subject>Enterocolitis, Pseudomembranous - therapy</subject><subject>Fecal microflora</subject><subject>Feces</subject><subject>Feces - microbiology</subject><subject>Female</subject><subject>Firmicutes</subject><subject>Follow-Up Studies</subject><subject>Gastroenterology</subject><subject>Genomes</subject><subject>Hospitals</subject><subject>Humans</subject><subject>Male</subject><subject>Medicine</subject><subject>Metagenome</subject><subject>Microbiota</subject><subject>Microorganisms</subject><subject>Middle Aged</subject><subject>Patients</subject><subject>Recurrent infection</subject><subject>RNA, Ribosomal, 16S</subject><subject>rRNA 16S</subject><subject>Staphylococcus infections</subject><subject>Transplantation</subject><subject>Transplants & implants</subject><subject>Treatment Outcome</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>DOA</sourceid><recordid>eNptUs1u1DAYjBCIlsIbILDEhcsu_kkc-4KEVgUqFXGBs-XYn1uvkjjYTlHFy9fppqVFnGzZM_ONx1NVrwneEtaSD_swx1H32ymMsMVYEMbwk-qYSEY3nGL29MH-qHqR0h7jhgnOn1dHtGaY4ZodV3--eRND50PWyF6PevAmIT-iSWcPY04oR9AZLPrt8yVyYHSPhr-UHPWYpl6PueDDiFyIKIKZYyxktOtDytFbPw_Ieue88T0U9SKzoF9Wz5zuE7xa15Pq5-fTH7uvm_PvX852n843pqE8byS1xFgKvDEWM2oM5a5tpJa207i2rbYA0ArW4brBhBnhBC15GNnIlgjg7KR6e9Cdih-15pYUqTmRnBG6IM4OCBv0Xk3RDzpeq6C9uj0I8ULpmL3pQeFOO8lqInXHa-Oc5FZSXcaAENZYUbQ-rtPmbgBrShBR949EH9-M_lJdhCvFRL14KQLvV4EYfs2Qshp8MtCXlCHMt74bIlgxUaDv_oH-_3X1AVW-LaUI7t4MwWrp0h1LLV1Sa5cK7c3Dh9yT7srDbgByGsuI</recordid><startdate>20131126</startdate><enddate>20131126</enddate><creator>Song, Yang</creator><creator>Garg, Shashank</creator><creator>Girotra, Mohit</creator><creator>Maddox, Cynthia</creator><creator>von Rosenvinge, Erik C</creator><creator>Dutta, Anand</creator><creator>Dutta, Sudhir</creator><creator>Fricke, W Florian</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QO</scope><scope>7RV</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TG</scope><scope>7TM</scope><scope>7U9</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>KB0</scope><scope>KL.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>M7S</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PATMY</scope><scope>PDBOC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20131126</creationdate><title>Microbiota dynamics in patients treated with fecal microbiota transplantation for recurrent Clostridium difficile infection</title><author>Song, Yang ; Garg, Shashank ; Girotra, Mohit ; Maddox, Cynthia ; von Rosenvinge, Erik C ; Dutta, Anand ; Dutta, Sudhir ; Fricke, W Florian</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c526t-92d1cd2e65cd032cc26f759a9dba04d7adeee783b045013c8f82008c959718e63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Aged</topic><topic>Anti-Bacterial Agents - pharmacology</topic><topic>Antibiotics</topic><topic>Bacteria</topic><topic>Biodiversity</topic><topic>Biological Therapy - methods</topic><topic>Clostridium difficile</topic><topic>Colitis</topic><topic>Diarrhea</topic><topic>Disease</topic><topic>Enterocolitis, Pseudomembranous - microbiology</topic><topic>Enterocolitis, Pseudomembranous - therapy</topic><topic>Fecal microflora</topic><topic>Feces</topic><topic>Feces - microbiology</topic><topic>Female</topic><topic>Firmicutes</topic><topic>Follow-Up Studies</topic><topic>Gastroenterology</topic><topic>Genomes</topic><topic>Hospitals</topic><topic>Humans</topic><topic>Male</topic><topic>Medicine</topic><topic>Metagenome</topic><topic>Microbiota</topic><topic>Microorganisms</topic><topic>Middle Aged</topic><topic>Patients</topic><topic>Recurrent infection</topic><topic>RNA, Ribosomal, 16S</topic><topic>rRNA 16S</topic><topic>Staphylococcus infections</topic><topic>Transplantation</topic><topic>Transplants & implants</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Song, Yang</creatorcontrib><creatorcontrib>Garg, Shashank</creatorcontrib><creatorcontrib>Girotra, Mohit</creatorcontrib><creatorcontrib>Maddox, Cynthia</creatorcontrib><creatorcontrib>von Rosenvinge, Erik C</creatorcontrib><creatorcontrib>Dutta, Anand</creatorcontrib><creatorcontrib>Dutta, Sudhir</creatorcontrib><creatorcontrib>Fricke, W Florian</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Proquest Nursing & Allied Health Source</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Meteorological & Geoastrophysical Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Agricultural Science Collection</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science & Engineering Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>Agricultural & Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Materials Science Database</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Meteorological & Geoastrophysical Abstracts - Academic</collection><collection>ProQuest Engineering Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Agricultural Science Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>Materials Science Collection</collection><collection>Access via ProQuest (Open Access)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Engineering Collection</collection><collection>Environmental Science Collection</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Song, Yang</au><au>Garg, Shashank</au><au>Girotra, Mohit</au><au>Maddox, Cynthia</au><au>von Rosenvinge, Erik C</au><au>Dutta, Anand</au><au>Dutta, Sudhir</au><au>Fricke, W Florian</au><au>Berg, Gabriele</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Microbiota dynamics in patients treated with fecal microbiota transplantation for recurrent Clostridium difficile infection</atitle><jtitle>PloS one</jtitle><addtitle>PLoS One</addtitle><date>2013-11-26</date><risdate>2013</risdate><volume>8</volume><issue>11</issue><spage>e81330</spage><epage>e81330</epage><pages>e81330-e81330</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract>Clostridium difficile causes antibiotic-associated diarrhea and pseudomembraneous colitis and is responsible for a large and increasing fraction of hospital-acquired infections. Fecal microbiota transplantation (FMT) is an alternate treatment option for recurrent C. difficile infection (RCDI) refractory to antibiotic therapy. It has recently been discussed favorably in the clinical and scientific communities and is receiving increasing public attention. However, short- and long-term health consequences of FMT remain a concern, as the effects of the transplanted microbiota on the patient remain unknown. To shed light on microbial events associated with RCDI and treatment by FMT, we performed fecal microbiota analysis by 16S rRNA gene amplicon pyrosequencing of 14 pairs of healthy donors and RCDI patients treated successfully by FMT. Post-FMT patient and healthy donor samples collected up to one year after FMT were studied longitudinally, including one post-FMT patient with antibiotic-associated relapse three months after FMT. This analysis allowed us not only to confirm prior reports that RCDI is associated with reduced diversity and compositional changes in the fecal microbiota, but also to characterize previously undocumented post-FMT microbiota dynamics. Members of the Streptococcaceae, Enterococcaceae, or Enterobacteriaceae were significantly increased and putative butyrate producers, such as Lachnospiraceae and Ruminococcaceae were significantly reduced in samples from RCDI patients before FMT as compared to post-FMT patient and healthy donor samples. RCDI patient samples showed more case-specific variations than post-FMT patient and healthy donor samples. However, none of the bacterial groups were invariably associated with RCDI or successful treatment by FMT. Overall microbiota compositions in post-FMT patients, specifically abundances of the above-mentioned Firmicutes, continued to change for at least 16 weeks after FMT, suggesting that full microbiota recovery from RCDI may take much longer than expected based on the disappearance of diarrheal symptoms immediately after FMT.</abstract><cop>United States</cop><pub>Public Library of Science</pub><pmid>24303043</pmid><doi>10.1371/journal.pone.0081330</doi><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1932-6203 |
ispartof | PloS one, 2013-11, Vol.8 (11), p.e81330-e81330 |
issn | 1932-6203 1932-6203 |
language | eng |
recordid | cdi_plos_journals_1461963126 |
source | MEDLINE; DOAJ Directory of Open Access Journals; Public Library of Science (PLoS) Journals Open Access; EZB-FREE-00999 freely available EZB journals; PubMed Central; Free Full-Text Journals in Chemistry |
subjects | Aged Anti-Bacterial Agents - pharmacology Antibiotics Bacteria Biodiversity Biological Therapy - methods Clostridium difficile Colitis Diarrhea Disease Enterocolitis, Pseudomembranous - microbiology Enterocolitis, Pseudomembranous - therapy Fecal microflora Feces Feces - microbiology Female Firmicutes Follow-Up Studies Gastroenterology Genomes Hospitals Humans Male Medicine Metagenome Microbiota Microorganisms Middle Aged Patients Recurrent infection RNA, Ribosomal, 16S rRNA 16S Staphylococcus infections Transplantation Transplants & implants Treatment Outcome |
title | Microbiota dynamics in patients treated with fecal microbiota transplantation for recurrent Clostridium difficile infection |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-03T20%3A48%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Microbiota%20dynamics%20in%20patients%20treated%20with%20fecal%20microbiota%20transplantation%20for%20recurrent%20Clostridium%20difficile%20infection&rft.jtitle=PloS%20one&rft.au=Song,%20Yang&rft.date=2013-11-26&rft.volume=8&rft.issue=11&rft.spage=e81330&rft.epage=e81330&rft.pages=e81330-e81330&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0081330&rft_dat=%3Cproquest_plos_%3E3138466251%3C/proquest_plos_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1461963126&rft_id=info:pmid/24303043&rft_doaj_id=oai_doaj_org_article_0baf93419ab64cff96d92a8e6e88dcd8&rfr_iscdi=true |